Amrion magnesium, boron osteoporosis claims unapproved health, drug claims -- FDA.
This article was originally published in The Tan Sheet
Executive Summary
AMRION MAGNESIUM, BORON OSTEOPOROSIS CLAIMS ARE DRUG CLAIMS, FDA tells the company in a Dec. 1 "courtesy letter" recently made available by the agency. Amrion had filed structure/function claims regarding a link between various substances and osteoporosis for its HealthSmart Daily Essentials, HealthSmart Calcium Carbonate and HealthSmart Calcium & Magnesium Complex. "These statements are not statements of nutritional support subject to section 403(r)(6) of the [Food, Drug & Cosmetic Act], but are health claims subject" to another section of the act, FDA stated. Supplement manufacturers are only permitted to make health claims for calcium and osteoporosis. Amrion plans to make all of the modifications requested by FDA.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning